ImmunoCellular Therapeutics

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its development pipeline consists of multiple programs and clinical indications at various stages of development. The company was founded by Eli Goldberger and is headquartered in Montvale, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company, which engages in the development of drugs with the potential to transform therapeutic paradigms. Its pipeline includes EOM613 and EOM147. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613.

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

MONTVALE, N.J. and LOS ANGELES, Dec. 2, 2021 /PRNewswire/ -- EOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd.

EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement

LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021.

ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market

News for ImmunoCellular Therapeutics Stock (IMUC)